The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...